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A bstrac t
Recently a molecular model was proposed lor the binding site of the antagonist 3M -  )-/V-(2,3-dihydro-l-mediyl-2-oxo-5~phenyl-l H-
1,4-benzodia/epine- 3 s I) I / /  mdole 2-c^ 'hoxam ide (deva/epide) on the cholecystokinin-A (C C K A) receptor (Van der Bent et al., 1994. 
Drug Design Discov. 12, 129 14X). Fifteen amino acids were identified, including hydrophilic ones such as S e ru ‘\  Asivw  and S e r '71\  
that might interact with the caihoxam ide moiety in deva/epide. To provide mutational evidence for this model, wild-type and mutant 
receptors (S139A, N349A and S379A ) were transiently expressed and compared with respect to the ability of devazepide to inhibit 
binding of radiolabelled cholecystokinin <2(> 33)^peptkle amide (CCK^S) mid CCK-H-evoked (V  1 mobilization. The data presented 
suggest the involvement of the three residues in antagonist binding, although to a different extent. However, it does not seem likely that 
hydrogen bonds are the driving force in view of the relatively minor changes in receptor affinity and activity. £9 1997 Elsevier Science
B.V.
Keywords: ( ’H i )  (Chinese  h a n d le r  ova i )  l cell;  Cholecystukiniu;  C C K N receptor; Deva/epide;  l .-3h4,7IK; ( ' i r  ‘ mobilization; Cell recruitment; Receptor  
modelline
1. Introduction
Receptors interacting with the cholecystokinin (CCK) 
and gastrin families of peptides are widely expressed 
throughout the gastrointestinal and nervous system (Wank, 
1995). Recent primary amino acid sequence deduction of 
various CCK receptor cDNAs has strengthened previous 
pharmacological evidence for the existence of two receptor 
subtypes, designated CCK s and C C K H, the latter being 
identical to the gastrin receptor, The CCK x receptor pre­
dominates in the gastrointestinal tract, whereas the C’CKj, 
receptor is predominantly distributed throughout the brain 
and spinal cord. The extensive regulatory role of CCK in 
the gastrointestinal tract has stimulated the interest in 
developing receptor ligands with (ant)agonistic modes of 
action for the treatment of several gastrointestinal disor­
ders (Wank, 1995). Thus far, two CCK A receptor antago-
Corrcsponding author. T e l: CM 24) V >1 45X9 ; K i\: U C 24) 3544)525; 
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nists, loxiglumide (Meyer et al., (989) and devazepide 
(3M -  )-AM2,3-dihydro-l-methyl-2-oxo-5-phcnyI-l W-1,4- 
benzodia/.epine-3-yl)-l //-indole-2-carboxaniide; Lidclle et 
al., 1989), have entered clinical studies. However, caution 
should be taken since animal toxicity studies revealed that 
long-term treatment with devazepide may lead to serious 
side effects (Iversen et al., 1991).
In order to provide a more rational approach towards 
the design of receptor antagonists, Van der Bent et al. 
(1994) previously built a bacteriorhodopsin-hased model 
of the membrane-embedded part of the CCKA receptor in 
which they identified a putative antagonist binding site on 
the basis of the structure-activity relationships and confor­
mational characteristics of the two parent classes of CCKA 
receptor antagonists, lorglumide and devazepide. The most 
prominent feature of the proposed antagonist binding site 
is the presence of a hydrogen acceptor, the existence of 
which is concluded from the observation that the affinity 
of devazepide is highly dependent on the presence of a 
hydrogen atom on the exoeyclic amide bond that connects 
the benzodiazepine and indole systems (Hvans et al., 1988).
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Both replacement of this hydrogen by a methyl group and 
that of the entire amide bond by a methylene bridge results
sion an d /o r  immunocytochemistry. Briefly, CHO cells 
were cultured in Dulbecco’s modified Engle’s medium
in an affinity loss of over 4 log units. Potential hydrogen (DMEM) supplemented with 10% ( v /v )  [octal calf serum
acceptors are S er139 (H3), T h r132 (H3), Asn349 (H6), S e r375 in a humidified atmosphere of 5% C 0 2 at 37°C. For
transfection, CHO cells were grown to 70% confluency, 
trypsinized and transferred to a cuvette (3 X I0ft cells/300 
|xl). The cells were electroporated (250 V, 960 |xF) in the
(H7) and S er379 (H7). O f these, Ser139, located nearly 
half-way helix 3 (H3) in the interior of the receptor pore, is 
the most likely candidate since attempts to dock de-
vazepide with hydrogen bonds to Asn349, S e r375 and S e r379 presence of 20 jxg of pTEJ8 containing full-length wild- 
failed, whereas T hr132 was regarded as unlikely because of type or mutated CCKA receptor cDNA. Based on the
ability of transfected cells to respond to a maximal concen­
tration of CCK-8 with an increase in cytosolic free calcium 
concentration we routinely obtained a transfection effi­
ciency of about 70%* Similar values were reached with the 
CCK b receptor and the histamine receptor. In initial stud­
ies using immunocytochemistry following transfection with 
a pSG5-derived vector expressing the extracellular part of 
CD45 containing a vsv-tag a considerably lower value of
its location close to the extracellular end of the pore. Othero
amino acids, which» because of their location within 4 A of 
the predicted docking site, form part of the putative antag­
onist binding site, are: Phe112, Phe13\  M e t136, S e r143, 
T rp 181, Ser184, Leu232, T rp342, lie345, Leu372 and T yr376, 
The present study aims to validate the proposed model 
for the antagonist binding site of the C C K A receptor. To 
this end Ser139, Ser379 and Asn349 were individually mu­
tated into Ala. Mutated receptors were transiently ex- 30% was obtained. This suggests that receptor proteins can 
pressed in Chinese hamster ovary (CHO-K1) cells and the 
potency of devazepide to inhibit the binding of radiola­
belled cholecystokinin-(26~33)-peptide amide (CCK-8) 
and the increase in the intracellular Ca2+ concentration 
([Ca24];) in response to CCK-8 was determined. The data 
presented suggest that the three residues are indeed in­
volved in antagonist binding. However, the relatively small 
changes in receptor affinity and activity disfavour a role 
for hydrogen bonds as a driving force.
2. Materials and methods
2.7. Mutagenesis o f  CCKA receptor cDNA
Full-length cDNA encoding the rat C C K A receptor, 
truncated to within three nucleotides of the first in frame 
ATG (Yule et ah, 1993) and subcloned into the mam­
malian expression vector pTEJ8, was kindly provided by 
Dr. C.D. Logsdon (University of Michigan, Ann Arbor, 
MI, USA). Oligonucleotides for mutagenesis are 5'-
C T A C T T C A T G G G T A C C G C C G T G A G C G T T T - 3 '  
(S 139A), 5 '-C C T A C A C C TC C G C C TG TG TG A A C C C - 
CATCATC-3' (S379A) and 5'-ATCTTCAGCGCTG- 
CAGCCTGGCGG-3' (N349A). Mutations were introduced 
by the T7-GEN site-directed mutagenesis kit from US 
Biochemical (Cleveland, OH, USA) and confirmed by 
sequencing. For transfection, cDNA was subcloned into 
the H m dlll and BamHI sites of the mammalian expression 
vector pTEJ8.
2.2. Transfection o f CHO cells with cDNA o f  the CCKA 
receptor
Chinese hamster ovary (CHO)-Kl cells were trans­
fected with cDNA of the C C K A receptor essentially as 
described in ‘Methods in Electroporation’ (Bio-Rad). With 
this method, transfection efficiencies of 50% to 100% have
already be detected at relatively low expression levels by 
virtue of their ability to efficiently stimulate second mes­
senger production, whereas considerably higher expression 
levels are needed for immunocytochemical detection.
23. Fluorescence measurements in individual CHO cells
Transfected cells were grown for 24 h, trypsinized and 
seeded on a glass coverslip (2 X 10*1 ce lls /30  fil). The 
cells were allowed to attach for 30 min. Culture medium 
was added and the cells were grown to subconfluency for 
24 h. For fluorescence measurements, the cells were incu­
bated with 2 jxM l-[2-(5-carboxyoxazol-2-yl)-6-aniino- 
benzofuran-5-oxy]-2-(2'-amino-5'-methylphenoxy)-ethane- 
jV, N, N \  N'-tetraacetic acid pentaacetoxy methylester 
(fura-2/AM) for 30 min at 37°C. To remove non-hydro- 
lysed dye, cells were washed 3 times with a physiological 
salt solution containing 137 mM N aC l 4.7 mM KC1, 0.56 
mM MgCU, 1.28 mM CaCU, 1.0 mM N a2H P04, 2 mM 
L-glutamine, 5.5 mM P-glucose, 0.1% (w /v )  bovine serum 
albumin and 10 mM HEPES (pH 7.4). Coverslips were 
mounted in a thermostatic (34°C) perfusion chamber, 
placed on the stage of an inverted microscope (Nikon 
Diaphot). Superfusion was at a How rate of I ml/ min. 
Routinely, an epifluorescent 40 X magnification oil im­
mersion objective was used to allow simultaneous monitor­
ing of an average of close to 80 individual cells. Dynamic 
video imaging was carried out as described previously 
(Willems et al., 1993a) using the MagiCal hardware and 
TARDIS software provided by Joyce Loebl (Dukesway, 
Team Valley, Gateshead, UK). The fluorescence emission 
ratio at 492 mn was monitored as a measure of [Ca2+]j 
after excitation at 340 and 380 nm.
2.4. Fluorescence measurements in suspensions of CHO 
cells
Transfected CHO cells were seeded in 25 cm2 culture
been reported in CHO cells as judged from (i-gal expres- flasks (1 X 10ft cells/flask) and grown for 48 h. The cells
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were trypsinized and washed twice in a HEPES/Tris 
medium containing 133 mM NaCl, 4.2 mM KC1, 1.0 mM 
CaCl2, i.O mM MgCK, 5.8 mM glucose, 0.2 m g /m l
soybean trypsin inhibitor, an amino acid mixture according 
to Eagle, 0.1% (w /v )  bovine serum albumin and 10 mM 
HEPES, adjusted with Tris to pH 7.4. Cells were resus­
pended in HEPES/Tris medium containing 1% (w /v )  
bovine serum albumin and loaded with 2 jxM fura-2/A M  
for 20 min at 37°C. Excess fu ra-2 /A M  was removed by 
washing the cells twice with H E PE S/T ris  medium con­
taining 0.1% (w /v )  bovine serum albumin. Cells were 
transferred to a cuvette placed in a Shimadzu RF-5000 
spectrofluorophotometer equipped with a magnetic stirrer 
and a thermostated cuvette holder. Fluorescence measure­
ments were carried out at 37°C as described previously 
(Willems et al., 1993a,b). The fluorescence emission ratio 
at 490 nm was monitored as a measure of the average 
[Ca2+]: after excitation at 340 and 380 nm.
maximal devazepide concentrations for the inhibition of 
[125I]CCK-8 binding were calculated by means of the 
nonlinear regression computer program InPlot (Graphpad 
Software for Science, San Diego, CA, USA).
2.7. Materials
Tissue culture medium and additives were purchased 
from Gibco BRL (Paisley, UK) and fu ra -2 /A M  from 
Molecular Probes (Eugene, OR, USA). Soybean trypsin 
inhibitor and CCK-8 were obtained from Sigma Diagnos­
tics (St. Louis, MO, USA) and devazepide (L~364,718) 
from Merck (Darmstadt, Germany). [ ,25I]CCK~8 (2200 
C i/m m ol)  was purchased from NEN Research Products 
(Boston, MA, USA) and G F /B  filters from Whatman 
(Maidstone, UK). All other chemicals were of reagent 
grade.
2.5. Radioligand binding studies 3. Results
Transfected CHO cells, cultured for 48 h, were washed 
twice with 20 mM sodium phosphate buffer (pH 7.8). 
After scraping, the cells were rcsuspended in 50 mM 
Tris/HCl (pH 7.8) containing 0.3 m g /m l soybean trypsin 
inhibitor and freeze-thawed 3 times using liquid nitrogen. 
The suspension was centrifuged at I 0 0 0 0 X #  (Eppendorf 
minifuge) for I h at 4°C. The pellet was resuspended in 50 
mM Tris/HCI (pH 7.8). Binding studies were performed 
as described previously (IJzerman and Melman, 1992). 
Briefly, 100 juul of membrane suspension (40 |xg protein) 
were added to 300 jxl of an assay buffer containing (final 
concentrations) 3.75 mM M gCI2, 0.0375% ( w /v )  3-[(3- 
cholamidopropyl) dimethylammonio] l-propanesulfonate, 
50 pM [125l]CCK-8, the indicated concentration of de­
vazepide (L-364.718) and 7.5 mM HEPES (pH 7.4) and 
incubated for 30 min at 37°C. The reaction was quenched 
by the addition of 1 ml of ice-cold 'stop solution' contain­
ing 5 mM MgCK and 10 mM HEPES (pH 7.4) followed 
by rapid filtration through pre-soaked Whatman G F /B  
filters. The filters were washed 3 times with 2 ml ice-cold 
stop solution and taken up in scintillation fluid. Radioactiv­
ity retained on the filters was determined by liquid scintil­
lation counting. Total binding and non-specific binding 
were determined with 0.1 pM and 0.1 fxM CCK-8, respec­
tively, Values presented are expressed as percentage of 
specific binding ([total binding] -  [non-specific binding]).
2,6. Data analysis and statistics
The results presented are the mean ±  S.E. of the num­
ber of experiments indicated in the text. Paired Student’s 
/-tests were used to determine statistical differences ( P  < 
0.05), Half-maximal CCK-8 concentrations for the recruit­
ment of individual cells in terms of Ca2+ mobilization and 
the increase in [Ca2+]s in suspensions of cells and half-
3,L Effect o f  receptor mutations on the inhibition by 
devazepide o f  the specific binding o f  [ 125IICCK-8 to mem­
branes o f  CHO cells transiently expressing the CCKA 
receptor
Devazepide inhibited specific binding of radiolabelled 
CCK-8 to wild-type membranes dose-dependently. The 
IC5() was calculated to be 0.96 nM (S.E. =  0.11; n =  5) 
(Fig. 1). Similarly, devazepide inhibited specific binding of 
[ l3iil]CCK-8 to membranes o f  the S139A and S379A mu­
tant with IC5() values o f  1.33 nM (S.E, =  0.25; n =  5) and 
0.73 nM (S.E. =  0.04; n =  5), respectively. Although the
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Fig. i. Inhibition of [ ,25I]CCK-8 binding to membranes from CHO cells 
transiently expressing wild-type or mutant CCKA receptors by de­
vazepide. Membranes from CHO cells transiently expressing wild-type or 
mutant CCKA receptors were incubated with 50 pM [ l25l]CCK-8 in the 
presence of various concentrations of devazepide for 30 min at 37°C, For 
each membrane preparation* specific binding, i.e. the difference between 
maximal binding in the presence of 0.1 pM CCK-8 and aspecific binding 
in the presence of 0.1 jjlM  CCK-8, is set at 100%, to which all other 
values, after correction for aspecific binding, are related. # Significantly 
different from the mutant S379A receptor.
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difference between the latter two IC 50 values is small, it is 
statistically significant. On the other hand, both values are 
not significantly different from that obtained with the 
wild-type receptor. Compared to wild-type membranes, 
specific labelling, expressed in cpm per mg of protein, 
with membranes from the mutant receptors S139A, S379A 
and N349A and mock-transfected cells amounted to
= 4), 75.3% (S.E. =  5.0; n =  4),118.0% (S.E. = 24.4; n ~
2.6% (?? =  1) and 0.3% (S.E. =  1.0; n = 3), respectively. 
The low value obtained with the N349A mutant receptor 
suggests that affinity a n d /o r  expression of this receptor is 
markedly reduced. No specific binding was observed with 
mock-transfected CHO-K1 cells.
3.2. Effect o f  receptor mutations on the inhibition by 
devazepide o f  the recruitment o f  CHO cells transiently 
expressing the CCK A receptor in terms o f  CCK-8-evoked 
Ca2 + mobilization
CCK-8 evoked a rapid increase in [Ca2* ^  in CHO-K1 
cells transiently expressing the wild-type C C K A receptor 
(Fig. 2). CCK-8 increased the number of responding cells 
dose-dependently (E C 50 =  78 pM) to a maximum of 68% 
(S.E. =  7.5, n =  5) reached with 10 nM CCK-8 (Fig. 3, 
upper left). The number of responding cells remained 
unchanged upon a further increase in the CCK-8 concen­
tration (data not shown). In each experiment, the number 
of cells responding to 10 nM CCK-8 was set at 100%, to 
which all other values were correlated. These cells are 
referred to as CCK-8-recruitable ceils. Similarly to the 
wild-type receptor, cells transfected with the mutant S 139A 
receptor (Fig. 3. upper right) or the mutant S379A receptor 
(Fig. 3, lower left) were recruited by CCK-8 in a dose-de­
pendent manner (EC50 values of 61 pM and 101 pM, 
respectively). Both E C sn values did not significantly differ 
from that obtained with the wild-type receptor, neither did 
the number of CCK-8-recruitable cells. In contrast, the
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Fig. 2. CCK-8-induced increase in free cytosolic Ca2+ concentration in a 
single CHO cell transiently expressing the wild-type CCKA receptor. 
CHO cells, transiently expressing wild-type CCKA receptors, were loaded 
with fura-2 and changes in fluoresccnce emission ratio 340/380 nm, 
reflecting changes in [Ca2+ ]h were monitored by digital imaging mi­
croscopy. The cells were superfused with physiological sail solution and 
stimulated with 10 nM CCK-8 for the indicated period of time.
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Fig. 3. Effect of dcvazepide on the dose-response curve for the CCK-8- 
induced recruitment of individual CHO cells transiently expressing wild- 
type or mutant CCKA receptors. CHO cells, transiently expressing wild- 
type or mutant CCKA receptors, were loaded with fura-2 and superfused 
with physiological salt solution containing either 3 nM dcvazepide (closed 
circles) or 0.1% (v /v )  dimethyl sulfoxide (open circles). Ai 1 min, the 
cells were stimulated with the indicated concentrations of CCK-8 for 5 
min. In each experiment, the number of wild-type-lransfected cells dis­
playing an increase in free cytosolic Ca2 + concentration in response to 
stimulation with 10 nM CCK-8, referred to as CCK-8 recruitable cells, is 
set at 100%, to which all other values are related. Upper panels: (left) 
wild-type receptor, (right) mutant SI39A receptor; lower panels: (left) 
mutant S379A receptor and (right) mutant N349A receptor. The values 
presented are the mean ±  S.E. of four transfections. In case of the mutant 
N34C)A receptor the values presented are the mean of two transfections. 
* Significantly different from corresponding control (P  <0.05).
EC50 value obtained with the mutant N349A receptor was 
80-fold increased to 6.2 nM (Fig. 3, lower right). The latter 
value was calculated under the assumption that with higher 
CCK-8 concentrations the 100% value would be reached.
Devazepide (3 nM), when added 1 min prior to stimula­
tion with CCK-8, caused the dose-recruitment curve of 
cells transfected with the wild type CCK A receptor to shift 
to the right (Fig. 3, upper left). The EC5() value was 
calculated to be increased 19-fold to a value of 1,5 nM. 
With the mutant S379A receptor an even higher (50-fold) 
increase in the E C 5() value was observed to a value of 5.1 
nM (Fig. 3, lower left). By contrast, cells transfected with 
the mutant S139A receptor were relatively insensitive to 3 
nM devazepide (Fig, 3, upper right). The EC 5() value was 
calculated to be 0.13 nM, representing a 2-fold increase 
only. The E C 50 value obtained with the mutant N349A 
receptor remained virtually unchanged in the presence of 
the receptor antagonist (EC5() values of 6.2 nM and 6.9 nM 
CCK-8 in the absence and presence of 3 nM devazepide, 
respectively) (Fig. 3, lower right). Again, both values were
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calculated under the assumption that with higher CCK-8 
concentrations the 100% value would be reached. Unfortu­
nately, such higher CCK-8 concentrations could not be 
tested since they evoked a rise in [Ca2'h]j in part of the 
non-transfected CHO cells. The latter response was po­
tently inhibited by devazepide suggesting the involvement 
of a CCK a type of receptor. Fig. 4, in which for each 
single CCK-8 concentration the number of cells respond­
ing in the presence of devazepide is expressed as a per­
centage of that responding in the absence of the antagonist, 
shows that with the S I 39A mutant devazepide did not 
affect the number of ceils recruited by 0.1 nM CCK-8, 
whereas with the wild-type receptor and the S379A mutant 
devazepide inhibited recruitment by 40% and 70%, respec­
tively. At 0 .1 nM and 1 nM CCK-8, the percentage 
recruitable cells responding in the presence of devazepide 
was significantly less with the mutant S379A receptor as 
compared to the mutant S139A receptor.
3.3. Effect o f receptor mutations on the inhibition by 
devazepide o f the CCK-8-evokecl peak increase in average 
I C a ] j  in a suspension o f  CHO cells transiently express­
ing the CCKa receptor
CCK-8 transiently increased the fluorescence emission 
ratio in a suspension of fura-2-loaded CHO cells trans­
fected with the wild-type C C K A receptor, reflecting a 
transient increase in average [Ca21 ]; ([Ca2 f'] j av). The peak 
value of the transient increased with increasing of the 
CCK-8 concentration to reach a maximum at 10 nM 
CCK-8 (data not shown), in each experiment, the latter 
value was set at 100%, to which all other values were 
correlated. With the wild-type receptor the EC50 value was 
calculated to be 113 pM (Table 1). The peak increase in 
[Ca2+]i>av evoked by 10 nM CCK-8 was not significantly
0
140
if)
H - »
C
120
0
Ü 100
o cn
Oi
c
80
c
13 0a 60C
0 <D
a L _ 40tn o
u
cc
M —
o
20
0
y/~
§ •  = wiidtype 
O « S139A 
a -  S379A
7/'/~
- 1 0 - 9  - 8
log  [ C C K - 8 ]  (M)
Fig. 4. Rehuive inhibition of CCK-8-induced cell recruitment at differing 
CCK-8 concentrations by devazepide. For each individual CCK-8 concen­
tration the number of cells responding in the presence of devazepide is 
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of the antagonist. The data presented are obtained from the experiments 
described in the caption of Fig. 3. n Significantly different from the 
Want S379A receptor ( P < 0.05).
Table 1
Summary of the ECS0 values for the CCK-8-evoked increase in cytosolic 
free Ca" ' concentration obtained with wild-type and mutant CCKA 
receptors in cell recruitment studies and cell suspension measurements 
performed in the absence and presence of devazepide
Receptor — Devazepide -1- Devazepide Ratio
Cell recruitment studies
WT 78 pM 1.5 nM 19 X
S139 A 61 pM 0,13 nM 2 X
S379A 101 pM 5.1 nM 50 X
N349A 6.2 nM 6,9 nM IX
Cell suspension
measurements
WT 113 pM 25.8 nM 228 X
S139A 80 pM 4.6 nM 58 X
S379A 405 pM 0.27 |xM 667 X
N349A 8.2 nM 0.66 |xM 80 X
different between cells expressing the wild-type receptor 
and cells expressing the mutant S139A receptor or the 
mutant S379A receptor but was reduced by 50% in cells 
expressing the mutant N349A receptor. With the S I 39A 
mutant the E C 50 value was calculated to be decreased 
0.7-foJd to 80 pM, whereas with the S379A mutant this 
value was calculated to be increased 3.6-fold to 405 pM. 
With the N349A mutant the E C 50 value was calculated to 
be increased 73-fold to 8.2 nM, under the assumption, 
however, that with higher CCK-8 concentrations the 100% 
value will be reached,
Devazepide (3 nM), when added 3 min prior to stimula­
tion with CCK-8, caused the dose-response curve of cells 
transfected with the wild-type C C K A receptor to shift to 
the right. The peak increase obtained with 10 nM CCK-8 
was reduced by 60%. Under the assumption that with 
higher CCK-8 concentrations the 100% value will be 
reached, the E C 50 value was calculated to be increased 
228-fold to 25.8 nM (Table 1). With the mutant S379A 
receptor the peak increase obtained with 10 nM CCK-8 
was reduced by 75% and the E C 50 value was calculated to 
be increased 667-fold to 0.27 jjlM. With the mutant S I 39A 
receptor the peak increase obtained with 10 nM CCK-8 
was reduced by 40% and the E C 50 value was calculated to 
be 4.6 nM, representing a 58-fold increase only. De­
vazepide effectively inhibited the CCK-8-induced peak 
increase in [Ca2+]itliv in cells expressing the mutant N349A 
receptor. In the latter cells the peak increase obtained with 
10 nM CCK-8 was reduced by 85% and the E C 50 value 
was calculated to be increased 80-fold to 0.66 jxM.
4. Discussion
The aim of the present study was to investigate by 
site-directed mutagenesis the possible involvement of the 
hydrophilic residues S e r139, A sn349 and Ser379 in the bind­
ing of the C C K A receptor antagonist devazepide. Func­
98 IIL.L Smeets et al. /  European Journal of Pharmacology 325 (1997) 93-99
tional characteristics of the three mutants were compared 
to the wild-type receptor in three experimental setups, (i) 
inhibition of radioligand binding, (ii) inhibition o f  the 
CCK-8-evoked increase in [Ca2+]iav in a suspension of 
cells, and (iii) inhibition of CCK-8-evoked recruitment of 
individual cells in terms of receptor-mediated Ca2+ mobi­
lization.
In radioligand binding studies replacing Ser139 by ala­
nine slightly reduced devazepide binding. In contrast, the 
S379A mutation appeared to increase the affinity of de­
vazepide for the C C K a receptor* Although the IC 50 values 
obtained with both mutants did not statistically differ from 
the value obtained with the wild-type receptor, they did so 
from one another. With the N349A mutant both agonist 
and antagonist binding were drastically decreased, suggest- 
ing that this amino acid may be important in proper 
receptor expression.
In addition to studying the effect of the receptor muta­
tions on the ability of devazepide to displace radiolabelled 
CCK-8 in a membrane preparation, we investigated the 
effect of these mutations on the ability of devazepide to 
inhibit the process of receptor-mediated Ca2+ mobilization 
in intact cells, Basically, the same results were obtained 
with both approaches. Thus, compared to the wild-type 
receptor devazepide inhibited CCK-8-evoked Ca2 + mobi­
lization less effective with the mutant S139A and N349A 
receptor and more effective with the mutant S379A recep­
tor. From the observation that the receptor mutations af­
fected the ability of devazepide to displace radiolabelled 
CCK-8 in a membrane preparation and inhibit the process 
of receptor-mediated Ca2+ mobilization in intact cells in 
the same way it can be concluded that these mutations did 
not inteifere with the process of signal transduction.
Beside suspension measurements we performed cell 
recruitment studies to analyse the effect of receptor muta­
tions on devazepide inhibition of receptor-mediated Ca2 + 
mobilization. The advantage of this approach, which is 
based on the observation that agonists dose-dependently 
increase the number of responding cells (Willems et al., 
1993a, 1995; Smeets et al.s 1996), is that only cells that 
express the receptor are included. The present study shows 
that with CHO cells transiently expressing the C C K A 
receptor a transfection efficiency of close to 70% can be 
reached. Another benefit of this approach is that cells 
grown on coverslips do not have to be isolated and there­
fore are not at risk of being exposed to conditions that 
might damage the receptor. The present study clearly 
demonstrates that this approach can be of use to analyse 
the effect of receptor mutations on the relative ability of 
antagonists to inhibit agonist-evoked Ca2+ mobilization.
The data presented are in agreement with the idea that 
the three amino acids investigated in this study form part 
of the putative antagonist binding site, though most proba­
bly none of them in the role of hydrogen acceptor.
This is the first report on the use of mutant receptors to 
address the antagonist binding site of the C C K A receptor.
However, the importance of two other amino acids form­
ing part of the proposed antagonist binding site in de­
vazepide binding was recently demonstrated in a study in 
which C C K B receptor amino acids were replaced by the 
corresponding amino acids from the CCK A reccptor (Kopin 
et al., 1995; Jagerschmidt et al., 1996). For instance, when 
His381 in the rat C C K B receptor and its equivalent on 
position 376 in the human C C K B receptor were mutated to 
leucine, the corresponding amino acid on position 372 in 
the CCKA receptor, the affinity for devazepide was in­
creased (Kopin et al„ 1995; Jagerschmidt et al., 1996). 
Similarly, when Val349 in the human C C K B receptor and 
its equivalent on position 353 (position 354 according to 
Wank et al., 1992) in the rat C C K B receptor were mutated 
to isoleucine, the corresponding amino acid on position 
345 in the CCK A receptor, devazepide binding was in­
creased (Kopin et al., 1995; Beinborn et al., 1993; 
Malatynska et al., 1995). This suggests that these two 
amino acids, lie345 and Leu372, form indeed part of the 
proposed devazepide binding site. In the same way, the 
involvement of the amino acids T h r l3\  Gin225 and Phe346, 
located close to the proposed antagonist binding site in the 
rat CCKa receptor, in devazepide binding was demon­
strated (Kopin et al., 1995). Thus far, only one CCK 
receptor mutation has been described (Arg57 changed to its 
corresponding amino acid Gin59 in the rat C C K a receptor) 
outside the proposed CCKa receptor antagonist binding 
site that affected devazepide binding (Kopin et al., 1995).
Taken together the data reported in the literature and 
those obtained in the present study are in agreement with 
the proposed antagonist binding site of the CCKA receptor.
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